Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5) > Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5):432-5

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

ORIGINAL ARTICLE  


Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5):432-5

DOI: 10.23736/S0392-0488.17.05456-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

New formulation for topical treatment of onychomycoses

Elisa M. DIFONZO , Federica SCARFÌ, Massimiliano GALEONE

Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy


PDF  


BACKGROUND: In order to treat onychomycosis, topical and systemic medications are available. The choice of a systemic or topic treatment depends on numerous factors, such as patient’s age, the presence of comorbidity, responsible fungal species, the clinical form of onychomycosis, its location (fingernails or toenails), the number of nails affected and the percentage of the nail plate infected. As for topical medications, given that nail plate has an insufficiently permeable structure, it is necessary to use appropriate formulae that create in the surface of the nail plate a film able, in turn, to function both as an active ingredient’s deposit and moisturising agent in nail’s superficial layers in order to facilitate the spread of the active ingredient. In this manuscript, we wanted to evaluate the effectiveness and tolerability rate of a new topical formulation (Miconal Nails®, Morgan srl, Vicenza, Italy) composed of hydrogenated castor oil, hydroxyethyl cellulose, and other ingredients (urea, climbazole, piroctone olamine, undecylenic acid).
METHODS: We selected 25 patients of both sexes whose median age was between 20 and 70 years, and were affected by onychomycosis in a single toe. Their onychomycosis was a distolateral subungual type (with a <50% invasion of nail plate and sparing of lunula) and white superficial. The treatment was evaluated with the following possible outcomes: complete healing, improvement, stationarity, worsening.
RESULTS: Patients were 11 female subjects and 14 male subjects, whose median age was 45. A complete healing was achieved in 15 patients. In 3 cases the clinical presentation appeared unchanged with a persistence of mycological evidence. The response to the treatment was assessed as improvement in 7 patients.
CONCLUSIONS: In our experience, this new product is an effective weapon that enhances the therapeutic selection of topical formulae for treating onychomycosis. If used alone in the cases that meet inclusion criteria for topical treatment, it allowed us to achieve a complete healing just with a 5-month treatment in 60% of cases, data that reached 76% on the follow-up visit.


KEY WORDS: Onychomycosis - Nails - Therapeutics

inizio pagina

Publication History

Issue published online: September 12, 2017
Manuscript accepted: February 27, 2017
Manuscript revised: January 31, 2017
Manuscript received: September 7, 2016

Per citare questo articolo

Difonzo EM, Scarfì F, Galeone M. New formulation for topical treatment of onychomycoses. G Ital Dermatol Venereol 2017;152:432-5. DOI: 10.23736/S0392-0488.17.05456-6

Corresponding author e-mail

elisa.difonzo@uslcentro.toscana.it